ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1160

Antibody Predictors of Prognosis in a Large Multi-centre Cohort of Idiopathic Inflammatory Myopathy Associated Interstitial Lung Disease

Jennifer Hannah1, Alexandra Lawrence2, Jennifer Martinovic2, Marium Naqvi2, Saadia Sasha Ali3, Carmel Stock4, Cara Owens4, Anand Devaraj4, Louise Pollard2, Sangita Agarwal2, Belén Atienza-Mateo5, Amit Patel6, Alex West2, Kate Tinsley2, Hasti Robbie7, Felix Chua4, Boris Lams2, Athol Wells4, Sam Norton7, James Galloway7, Elisabetta Renzoni4 and Patrick Gordon8, 1King's College London, London, United Kingdom, 2Guy's and St Thomas' NHS Foundation Trust, London, United Kingdom, 3King's College Hospital, Epsom, United Kingdom, 4Royal Brompton and Harefield Hospitals NHS Trust, London, United Kingdom, 5Rheumatology, Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Spain, 6King's College Hospital, London, United Kingdom, 7King's College London, London, United Kingdom, 8NHS, London, United Kingdom

Meeting: ACR Convergence 2023

Keywords: Autoantibody(ies), Cohort Study, interstitial lung disease, Myositis, prognostic factors

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Monday, November 13, 2023

Title: (1155–1182) Muscle Biology, Myositis & Myopathies – Basic & Clinical Science Poster II

Session Type: Poster Session B

Session Time: 9:00AM-11:00AM

Background/Purpose: IIM-ILD follows a varied clinical course. Serological profile can help predict clinical phenotype, but impact on ILD prognosis is less clear. This multicentre UK cohort study examines whether serological profile can predict mortality and change in lung function over time.

Methods: Patients with IIM-ILD were identified in 3 NHS trusts from local databases. Adults with ILD meeting IIM diagnostic criteria or Interstitial Pneumonia with Autoimmune Features (IPAF) with Myositis Specific Antibodies (MSA) were included. Baseline characteristics from time of presentation were compared across antibody groups and across survivors/deceased at 2 years. Survival analysis looking at time to death (or lung transplant) for duration of available follow-up was modelled by Cox-Proportional Hazards comparing each antibody individually to all others. Models were adjusted for age, gender, ethnicity, presence of overlap CTD/malignancy, smoking and site. Regression models were also used to observe trends in lung function parameters over time.

Results: Of 430 included patients, 68% were female, 46% were of White ethnicity. 81% met IIM criteria, 19% were IPAF. Mean follow up duration was 4.3 years. Common antibodies were to Ro52, Jo1, PL12, MDA5 (n=195, 126, 44 & 32 respectively). 10% had evidence of pulmonary hypertension within 1 year of diagnosis, 4% had malignancy within 3 years. Baseline characteristics of survivors vs fatal cases at 2 years showed survivors were younger (51.4 vs 61.7 years), more likely to have never smoked (69% vs 44%), less likely to have been hospitalised at diagnosis (15% vs 52%) and had a lower Charleson Comorbidity Index. Survivors had lower CRP, higher CK & higher baseline FEV1/FVC/TLCO. Imbalance in age, BMI, CK and comorbidity status were seen across antibody groups. MDA5 had the highest adjusted hazard ratio (HR) for mortality of 4.59 (95%CI 2.10-10.01). Kaplan-Meier curve shows high early mortality in this group. Anti-synthetase antibodies (ARS) carried a reduced risk of mortality (HR 0.63), however individually Jo1 had low HR (0.61, 95%CI 0.4-0.87) and PL7 had high HR (2.07, 95%CI 1.44-2.99). RNP showed worse prognosis on adjusted analysis (HR 1.88, 95%CI 1.25-2.84) (Table 1). Regression models suggest that compared to other antibodies, %pred FVC in MDA5 improves over the first 3 years, in PL7 it drops, and in Jo1 it is no different (Figure 1). MDA5 % pred FEV1 also showed improvement, but in Ku it was lower than other antibodies from 21 months. There were no significant differences in % pred TLCO between antibodies.

Conclusion: There is strong evidence that antibody status associates with clinical outcomes, both in terms of progression of lung disease and mortality, suggesting pathogenetic differences. MDA5 predicts a high risk of death early on in disease course, whilst Jo1 associates with lower mortality. PL7 and RNP were additional antibodies associating with higher mortality. Difference between Jo1 and PL7 highlights variation within anti-synthetase syndrome. Paradoxically, if an MDA5 positive person survived the early disease phase, there was evidence that lung function can recover, which may reflect different MDA5 subpopulations.

Supporting image 1

Univariate and multivariate hazard ratios for primary endpoint of death/transplant according to presence or absence of each antibody. Statistically significant results are in bold type. *Counts of <5 suppressed to maintain anonymity

Supporting image 2

Kaplan-Meier survival curves for death/transplant according to antibody for the three antibodies showing statistically significant differences in survival on both univariate and multivariate analysis

Supporting image 3

Time trends in % predicted FVC in a) MDA5, b) PL7, and c) Jo1 using multi-level mixed effects models for repeated measures over time, showing slow improvement in MDA-5 FVC, whereas PL-7 deteriorates.


Disclosures: J. Hannah: None; A. Lawrence: None; J. Martinovic: None; M. Naqvi: None; S. Ali: None; C. Stock: None; C. Owens: None; A. Devaraj: Boehringer-Ingelheim, 2, Brainomix, 2; L. Pollard: None; S. Agarwal: None; B. Atienza-Mateo: None; A. Patel: None; A. West: None; K. Tinsley: None; H. Robbie: None; F. Chua: None; B. Lams: None; A. Wells: Boehringer-Ingelheim, 2, 6, Roche, 2, 6, Veracyte, 2, 6; S. Norton: Janssen, 6, Pfizer, 6; J. Galloway: AbbVie, 2, 5, 6, AstraZeneca, 5, Biogen, 6, Eli Lilly, 2, 5, 6, Galapagos, 2, 5, 6, Janssen, 2, 5, 6, Pfizer, 2, 5, 6, UCB, 2, 5, 6; E. Renzoni: None; P. Gordon: Celltrion, 12, Support to attend EULAR conference 2023, Galapagos, 1.

To cite this abstract in AMA style:

Hannah J, Lawrence A, Martinovic J, Naqvi M, Ali S, Stock C, Owens C, Devaraj A, Pollard L, Agarwal S, Atienza-Mateo B, Patel A, West A, Tinsley K, Robbie H, Chua F, Lams B, Wells A, Norton S, Galloway J, Renzoni E, Gordon P. Antibody Predictors of Prognosis in a Large Multi-centre Cohort of Idiopathic Inflammatory Myopathy Associated Interstitial Lung Disease [abstract]. Arthritis Rheumatol. 2023; 75 (suppl 9). https://acrabstracts.org/abstract/antibody-predictors-of-prognosis-in-a-large-multi-centre-cohort-of-idiopathic-inflammatory-myopathy-associated-interstitial-lung-disease/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2023

ACR Meeting Abstracts - https://acrabstracts.org/abstract/antibody-predictors-of-prognosis-in-a-large-multi-centre-cohort-of-idiopathic-inflammatory-myopathy-associated-interstitial-lung-disease/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology